# Lispro Mix 25 vs. Glargine in Type 2 Diabetics

> **NCT00551356** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 53 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Insulin lispro mix 25
- **DRUG:** Glargine

## Key facts

- **NCT ID:** NCT00551356
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2007-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551356, "Lispro Mix 25 vs. Glargine in Type 2 Diabetics". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00551356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*